Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.
Journal Article (Journal Article)
Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022;377:e069066. 35508320.
Full Text
Duke Authors
Cited Authors
- Kelsey, MD; Newby, LK
Published Date
- August 2022
Published In
Volume / Issue
- 175 / 8
Start / End Page
- JC86 -
PubMed ID
- 35914252
Electronic International Standard Serial Number (EISSN)
- 1539-3704
Digital Object Identifier (DOI)
- 10.7326/J22-0060
Language
- eng
Conference Location
- United States